20/20 Biolabs, Inc (AIDX) Fair Value & Analysis
Healthcare · US · Market cap $6.1M
20/20 Biolabs, Inc
AIDX · US
Fair value as of: Jun 23, 2026
From 3 valuation models · updated 7 days ago
Share price −31.4% over the past month.
Price vs Fair Value (4 months)
4‑month range $0.5841 – $24.44 · fair‑value band $0.3600 – $0.6000 · the $0.6118 price screens above the $0.4800 fair value. As of Jun 23, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
20/20 Biolabs, Inc (AIDX) currently trades at $0.6118, while our model-based Fair Value estimate is $0.4800 — implying the stock looks roughly 21.5% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $1.8M. Revenue declined 36.2% year over year. Net debt stands at $258M. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
20/20 Biolabs, Inc reported revenue of $2.0M in FY2025 versus $9.6M in FY2021, a compound −32.1%/yr. Reported net income was −$3.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $81.67 | $60.02 | -27% |
| Boston Scientific Corporation B1SX34 | R$229.30 | R$43.33 | -81% |
| Edwards Lifesciences Corporation EW | $85.98 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 20/20 Biolabs, Inc (AIDX) undervalued?
What is the fair value of AIDX?
What is the quality score of AIDX?
What is the revenue of 20/20 Biolabs, Inc (AIDX)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.